RCS - Roquefort Theraptcs. - Investor Presentation

Coiled Therapeutics

26/03/2026 13:00

RNS Number : 3083Y

Roquefort Therapeutics PLC

26 March 2026

 

26 March 2026

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Investor Presentation

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence of AO-252 from Coiled Therapeutics, Inc. and the name change to Coiled Therapeutics plc, effective 27 March 2026, the leadership team will host a live interactive presentation on the Engage Investor platform, on Monday 30 March 2026, at 2:00pm BST. 

 

Dr Sotirios Stergiopoulos, Chairman Coiled Therapeutics and Sridhar Vempati, CEO Coiled Therapeutics (together with Stephen West, current Chairman of Roquefort Therapeutics) will present.

 

The Company welcomes all current shareholders and interested investors to join, and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation.

 

Investors can sign up to Engage Investor at no cost and follow the Company from their personalised investor hub, and can register interest in this event here: 

https://engageinvestor.news/ROQ_IP_0326

 

 

-ENDS-

 

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman)
+44 (0)20 3918 8633
SP Angel Corporate Finance LLP (Joint Broker)
David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Shard Capital Partners LLP (Joint Broker)
Damon Heath
CPS Capital Group Pty Ltd (Joint Broker)
Jason Peterson / David Valentino
+44 (0)20 4530 6926
+61 (0)8 9223 2222
Burson Buchanan (Public Relations)
Henry Harrison Topham / Jamie Hooper / Toto Berger
+44 (0)20 7466 5000

 

LEI: ‎254900P4SISIWOR9RH34

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAUNAURNRUOUAR